Clinical Trials
10 trialsNCT00630552 2024-10-17
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
NantCell, Inc.
Phase 1/2 Completed
NCT00807612 2024-09-25
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT00819169 2024-08-20
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
Phase 1/2 Terminated
NCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01562899 2020-12-10
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01708161 2018-09-13
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Novartis
Phase 1/2 Terminated
NCT01479179 2016-10-26
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01473303 2016-06-28
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn